Related Experiment Video
Updated: Jun 25, 2026

Midface Hypoplasia and Cranial Base Morphology in Syndromic Craniosynostosis: A Comparative Analysis Study Using a Predictive Regression Model
Published on: November 4, 2025
Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone
Suk See De Ravin1, Elaine Shum, Kol A Zarember
1Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD 20892, USA. sderavin@niaid.nih.gov
Background:
X-linked severe combined immunodeficiency (XSCID) results from defects in the common cytokine receptor gamma chain (gamma c) required for signaling by receptors for interleukin (IL)-2, -4, -7, -9, -15, and -21. Following haploidentical bone marrow transplant without myelo-conditioning for XSCID, most patients achieve partial reconstitution often limited to T lymphocytes. Many partially corrected patients manifest extreme short stature (<5th percentile). Previous reports have implicated gamma c in growth hormone (GH) receptor signaling, thus severe growth failure in XSCID may be related to the underlying gamma c defect.
Aim:
To evaluate the GH/insulin-like growth factor-I (IGF-I) axis in three children with XSCID and partial immune reconstitution with profound growth failure.
Methods:
The IGF-I generation test was performed by administering recombinant GH subcutaneously for 5 days, and measuring serum levels for IGF-I before GH injection, and on days 5 and 8.
Results:
Study of the somatotropic axis revealed profoundly diminished IGF-I production following rGH challenge in all three patients.
Conclusion:
The data indicate that the GH/IGF-I axis in these partially corrected XSCID patients with severe short stature is profoundly impaired, and supports previous studies suggesting that the underlying gamma c defect may contribute to the severe growth failure in XSCID. This supports a role for defective gamma c in the extreme short stature of XSCID, and raises the possibility of recombinant IGF-I treatment to bypass this defect.
Insights
Children with X-linked severe combined immunodeficiency (XSCID) and short stature show impaired growth hormone (GH) and insulin-like growth factor-I (IGF-I) axis function. This suggests the gamma c defect contributes to growth failure, potentially treatable with IGF-I therapy.
Area of Science:
- Pediatric Endocrinology
- Immunology
- Genetics
Background:
- X-linked severe combined immunodeficiency (XSCID) stems from defects in the common cytokine receptor gamma chain (gamma c).
- Partial immune reconstitution after bone marrow transplant in XSCID patients often results in profound short stature.
- The gamma c chain's role in growth hormone (GH) receptor signaling suggests a link to growth failure in XSCID.
Observation:
- This study evaluated the GH/insulin-like growth factor-I (IGF-I) axis in three children with XSCID and severe short stature.
- An IGF-I generation test was performed using recombinant GH administration.
- Serum IGF-I levels were measured before and after GH challenge.
Findings:
- All three XSCID patients exhibited profoundly diminished IGF-I production following recombinant GH administration.
- The somatotropic axis was significantly impaired in these partially corrected XSCID patients.
Implications:
- The findings indicate a severely impaired GH/IGF-I axis in XSCID patients with short stature.
- This supports the hypothesis that the underlying gamma c defect contributes to extreme short stature in XSCID.
- Recombinant IGF-I treatment may be a viable therapeutic option to bypass the defective GH/IGF-I axis.
Related Concept Videos
Nature and Nurture
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Sex-linked Disorders
Signs of Puberty
Polygenic Traits
Incomplete Dominance
